Literature DB >> 25117407

Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium.

Megan DeNicola1, Jianfeng Du1, Zhengke Wang1, Naohiro Yano2, Ling Zhang3, Yigang Wang4, Gangjian Qin5, Shougang Zhuang6, Ting C Zhao7.   

Abstract

We have demonstrated that GLP-1 improved myocardial functional recovery in acute myocardial ischemic injury. However, whether stimulation of the GLP-1 receptor (GLP-1R) with exendin-4, a selective GLP-1R agonist, could initiate a protective effect in the heart remains to be determined. Mouse myocardial infarction (MI) was created by ligation of the left descending artery. After 48 h of MI, animals were divided into the following groups (n = 5-7/group): 1) sham (animals that underwent thoracotomy without ligation), 2) MI [animals that underwent MI and received a daily dose of intraperitoneal injection (ip) of saline]; and 3) MI + exendin-4 [infarcted mice that received injections of exendin-4 (0.1 mg/kg ip)]. Two weeks later, cardiac function was assessed by echocardiography and an isovolumetrically perfused heart. Compared with control MI hearts, stimulation of GLP-1R improved cardiac function, which was associated with attenuation of myocardial hypertrophy, the mitigation of interstitial fibrosis, and an increase in survival rate in post-MI hearts. Furthermore, H9c2 cardiomyoblasts were preconditioned with exendin-4 at a dose of 100 nmol/l and then subjected to hydrogen peroxide exposure at concentrations of 50 and 100 μmol/l. The exendin-4 treatment decreased lactate dehydrogenase leakage and increased cell survival. Notably, this event was also associated with the reduction of cleaved caspase-3 and caspase-9 and attenuation of reactive oxygen species production. Exendin-4 treatments improved mitochondrial respiration and suppressed the opening of mitochondrial permeability transition pore and protected mitochondria function. Our results indicate that GLP-1R serves as a novel approach to eliciting cardioprotection and mitigating oxidative stress-induced injury.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  exendin-4; glucagon-like peptide-1 receptor; heart; infarction; oxidant stress

Mesh:

Substances:

Year:  2014        PMID: 25117407      PMCID: PMC4200306          DOI: 10.1152/ajpendo.00109.2014

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  46 in total

1.  gp-91 mediates histone deacetylase inhibition-induced cardioprotection.

Authors:  Ting C Zhao; Ling X Zhang; Guangmao Cheng; Jun T Liu
Journal:  Biochim Biophys Acta       Date:  2010-04-28

2.  Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

Authors:  Amal K Bose; Mihaela M Mocanu; Richard D Carr; Christian L Brand; Derek M Yellon
Journal:  Diabetes       Date:  2005-01       Impact factor: 9.461

3.  Nuclear factor-kappaB-mediated cell survival involves transcriptional silencing of the mitochondrial death gene BNIP3 in ventricular myocytes.

Authors:  Delphine Baetz; Kelly M Regula; Karen Ens; James Shaw; Shilpa Kothari; Natalia Yurkova; Lorrie A Kirshenbaum
Journal:  Circulation       Date:  2005-12-13       Impact factor: 29.690

4.  Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition.

Authors:  L X Zhang; Y Zhao; G Cheng; T L Guo; Y E Chin; P Y Liu; T C Zhao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-09       Impact factor: 4.733

Review 5.  The association of heart failure with insulin resistance and the development of type 2 diabetes.

Authors:  John B Kostis; Michael Sanders
Journal:  Am J Hypertens       Date:  2005-05       Impact factor: 2.689

6.  Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity.

Authors:  Sihem Boudina; Sandra Sena; Brian T O'Neill; Prakash Tathireddy; Martin E Young; E Dale Abel
Journal:  Circulation       Date:  2005-10-25       Impact factor: 29.690

7.  Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies.

Authors:  Shin Tsunekawa; Naoki Yamamoto; Katsura Tsukamoto; Yuji Itoh; Yukiko Kaneko; Toshihide Kimura; Yoh Ariyoshi; Yoshitaka Miura; Yutaka Oiso; Ichiro Niki
Journal:  J Endocrinol       Date:  2007-04       Impact factor: 4.286

Review 8.  Mechanisms of action of glucagon-like peptide 1 in the pancreas.

Authors:  Máire E Doyle; Josephine M Egan
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

9.  Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy.

Authors:  Lazaros A Nikolaidis; Dariush Elahi; You-Tang Shen; Richard P Shannon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-15       Impact factor: 4.733

10.  Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane.

Authors:  Paolo Spallarossa; Paola Altieri; Paolo Pronzato; Concetta Aloi; Giorgio Ghigliotti; Antonio Barsotti; Claudio Brunelli
Journal:  J Pharmacol Exp Ther       Date:  2009-10-19       Impact factor: 4.030

View more
  20 in total

Review 1.  Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA.

Authors:  Dorrin Zarrin Khat; Mansoor Husain
Journal:  Curr Diab Rep       Date:  2018-06-09       Impact factor: 4.810

2.  Irisin plays a pivotal role to protect the heart against ischemia and reperfusion injury.

Authors:  Hao Wang; Yu Tina Zhao; Shouyan Zhang; Patrycja M Dubielecka; Jianfeng Du; Naohiro Yano; Y Eugene Chin; Shougang Zhuang; Gangjian Qin; Ting C Zhao
Journal:  J Cell Physiol       Date:  2017-05-03       Impact factor: 6.384

Review 3.  Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.

Authors:  Ashish Sarraju; Sun H Kim; Joshua W Knowles
Journal:  Curr Atheroscler Rep       Date:  2016-02       Impact factor: 5.113

Review 4.  Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.

Authors:  Ersilia M DeFilippis; Michael M Givertz
Journal:  Curr Heart Fail Rep       Date:  2016-06

5.  Sitagliptin attenuates inflammatory responses in lipopolysaccharide-stimulated cardiomyocytes via nuclear factor-κB pathway inhibition.

Authors:  Chien-Hung Lin; Chung-Ching Lin
Journal:  Exp Ther Med       Date:  2016-04-11       Impact factor: 2.447

6.  Protection against cardiac hypertrophy by geniposide involves the GLP-1 receptor / AMPKα signalling pathway.

Authors:  Zhen-Guo Ma; Jia Dai; Wen-Bin Zhang; Yuan Yuan; Hai-Han Liao; Ning Zhang; Zhou-Yan Bian; Qi-Zhu Tang
Journal:  Br J Pharmacol       Date:  2016-03-14       Impact factor: 8.739

Review 7.  Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure.

Authors:  Thiago A Salles; Leonardo dos Santos; Valério G Barauna; Adriana C C Girardi
Journal:  Int J Mol Sci       Date:  2015-02-16       Impact factor: 5.923

8.  Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice.

Authors:  Youfang Chen; Jianfeng Du; Yu Tina Zhao; Ling Zhang; Guorong Lv; Shougang Zhuang; Gangjian Qin; Ting C Zhao
Journal:  Cardiovasc Diabetol       Date:  2015-08-07       Impact factor: 9.951

9.  Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages.

Authors:  Mitchel Tate; Emma Robinson; Brian D Green; Barbara J McDermott; David J Grieve
Journal:  Basic Res Cardiol       Date:  2015-11-23       Impact factor: 17.165

10.  Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix.

Authors:  Emma Robinson; Roslyn S Cassidy; Mitchel Tate; Youyou Zhao; Samuel Lockhart; Danielle Calderwood; Rachel Church; Mary K McGahon; Derek P Brazil; Barbara J McDermott; Brian D Green; David J Grieve
Journal:  Basic Res Cardiol       Date:  2015-03-01       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.